JAB-3068 not checked
Jacobio Pharmaceuticals Co., Ltd.
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before (6 hours for PK days) and 2 hours after each dosing.”In the company’s words, NCT03518554 on ClinicalTrials.gov
- Tested for
- Non-small Cell Lung Cancer (2 trials), Head and Neck Cancer (2 trials), Esophageal Cancer (2 trials), Other Metastatic Solid Tumors (2 trials), Advanced Solid Tumor, Esophageal Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Main trialPhase 1/2
- “This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.”In the company’s words, NCT03565003 on ClinicalTrials.gov
Other drugs for Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 31 Jan 2023 | A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China | |
| Phase 1/2Completed | 29 Dec 2023 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | |
| Phase 1Completed | 3 Feb 2022 | A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026